CMH20
MCID: CRD147
MIFTS: 48

Cardiomyopathy, Familial Hypertrophic, 20 (CMH20)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Cardiomyopathy, Familial Hypertrophic, 20

MalaCards integrated aliases for Cardiomyopathy, Familial Hypertrophic, 20:

Name: Cardiomyopathy, Familial Hypertrophic, 20 56 13 71
Cmh20 56 12 73
Familial Hypertrophic Cardiomyopathy 20 29 6
Cardiomyopathy, Hypertrophic, 20 56 29
Hypertrophic Cardiomyopathy 20 12 15
Cardiomyopathy, Hypertrophic, Familial, Type 20 39
Cardiomyopathy, Familial Hypertrophic 20 73
Cardiomyopathy Familial Hypertrophic 20 12

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
cardiomyopathy, familial hypertrophic, 20:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0110326
OMIM 56 613876
OMIM Phenotypic Series 56 PS192600
MeSH 43 D024741
MedGen 41 C3151267
UMLS 71 C3151267

Summaries for Cardiomyopathy, Familial Hypertrophic, 20

UniProtKB/Swiss-Prot : 73 Cardiomyopathy, familial hypertrophic 20: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

MalaCards based summary : Cardiomyopathy, Familial Hypertrophic, 20, also known as cmh20, is related to immuno-osseous dysplasia and polycystic kidney disease 4. An important gene associated with Cardiomyopathy, Familial Hypertrophic, 20 is NEXN (Nexilin F-Actin Binding Protein), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Glucocorticoid receptor regulatory network. The drugs Propofol and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and liver, and related phenotypes are atrial fibrillation and cardiomyopathy

Disease Ontology : 12 A familial hypertrophic cardiomyopathy that hhas material basis in heterozygous mutation in the NEXN gene on chromosome 1p31.1.

More information from OMIM: 613876 PS192600

Related Diseases for Cardiomyopathy, Familial Hypertrophic, 20

Diseases in the Hypertrophic Cardiomyopathy family:

Cardiomyopathy, Familial Hypertrophic, 2 Cardiomyopathy, Familial Hypertrophic, 3
Cardiomyopathy, Familial Hypertrophic, 4 Cardiomyopathy, Familial Hypertrophic, 1
Cardiomyopathy, Infantile Hypertrophic Cardiomyopathy, Familial Hypertrophic, 6
Cardiomyopathy, Familial Hypertrophic, 25 Cardiomyopathy, Familial Hypertrophic, 8
Cardiomyopathy, Familial Hypertrophic, 10 Cardiomyopathy, Familial Hypertrophic, 11
Cardiomyopathy, Familial Hypertrophic, 12 Cardiomyopathy, Familial Hypertrophic, 13
Cardiomyopathy, Familial Hypertrophic, 14 Cardiomyopathy, Familial Hypertrophic, 15
Cardiomyopathy, Familial Hypertrophic, 7 Cardiomyopathy, Familial Hypertrophic, 9
Cardiomyopathy, Familial Hypertrophic, 16 Cardiomyopathy, Familial Hypertrophic, 17
Cardiomyopathy, Familial Hypertrophic, 18 Cardiomyopathy, Familial Hypertrophic, 20
Cardiomyopathy, Familial Hypertrophic, 21 Cardiomyopathy, Familial Hypertrophic, 26
Cardiomyopathy, Familial Hypertrophic 27 Hypertrophic Cardiomyopathy Due to Intensive Athletic Training
Rare Familial Disorder with Hypertrophic Cardiomyopathy

Diseases related to Cardiomyopathy, Familial Hypertrophic, 20 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 immuno-osseous dysplasia 10.4 ELN ALB
2 polycystic kidney disease 4 10.4 ELN ALB
3 aspiration pneumonitis 10.4 SLC22A4 ALB
4 prolapse of urethra 10.3 NEXN ELN ALB
5 riedel's fibrosing thyroiditis 10.3 CD4 ALB
6 cork-handlers' disease 10.3 CD4 ALB
7 chronic graft versus host disease 10.2 CD4 ALB
8 meningovascular neurosyphilis 10.2 CD4 ALB
9 generalized atherosclerosis 10.2 IL6 ALB
10 granulomatous hepatitis 10.2 CD4 ALB
11 aneruptive fever 10.2 IL13 ALB
12 aspiration pneumonia 10.2 SLC22A4 IL6 ALB
13 aortitis 10.2 IL6 ELN
14 gastrointestinal tuberculosis 10.2 CD4 ALB
15 aztreonam allergy 10.2 IL13 HCCS
16 carbapenem allergy 10.2 PPL IL13
17 intestinal tuberculosis 10.2 CD4 ALB
18 ceftriaxone allergy 10.2 IL13 HCCS
19 co-trimoxazole allergy 10.2 PPL IL13
20 anti-basement membrane glomerulonephritis 10.1 CD4 ALB
21 acute cholangitis 10.1 IL6 ALB
22 angular cheilitis 10.1 CD4 ALB
23 bladder diverticulum 10.1 ELN EGFL6
24 noma 10.1 CXCL8 ALB
25 actinomycosis 10.1 HCCS CD4 ALB
26 angioimmunoblastic lymphadenopathy with dysproteinemia 10.1 IL6 IL13
27 marasmus 10.0 CD4 ALB
28 cefuroxime allergy 10.0 PPL IL13 HCCS
29 abdominal tuberculosis 10.0 CD4 ALB
30 cefaclor allergy 10.0 IL13 HCCS ALB
31 hypopyon 10.0 IL6 CD4
32 toxicodendron dermatitis 10.0 HCCS CXCL8
33 lung abscess 10.0 IL6 CD4 ALB
34 hantavirus hemorrhagic fever with renal syndrome 10.0 IL6 CD4 ALB
35 hypersensitivity reaction type iii disease 10.0 IL6 CD4 ALB
36 norwegian scabies 10.0 IL13 CD4
37 pneumocystosis 10.0 IL6 CD4 ALB
38 cellulitis 10.0 PPL IL6 CD4
39 plasma protein metabolism disease 9.9 IL6 CD4 ALB
40 pericardium disease 9.9 IL6 CD4 ALB
41 chickenpox 9.9 IL6 CD4 ALB
42 coccidiosis 9.9 IL6 CD4 ALB
43 autoimmune disease of urogenital tract 9.9 IL6 CD4 ALB
44 pericardial effusion 9.9 IL6 CD4 ALB
45 lymph node disease 9.9 IL6 CD4 ALB
46 meningoencephalitis 9.9 IL6 CD4 ALB
47 plague 9.9 IL6 CD4 ALB
48 spinal cord disease 9.9 IL6 CD4 ALB
49 autoimmune disease of gastrointestinal tract 9.9 IL6 CD4 ALB
50 cranial nerve disease 9.9 IL6 CD4 ALB

Graphical network of the top 20 diseases related to Cardiomyopathy, Familial Hypertrophic, 20:



Diseases related to Cardiomyopathy, Familial Hypertrophic, 20

Symptoms & Phenotypes for Cardiomyopathy, Familial Hypertrophic, 20

Human phenotypes related to Cardiomyopathy, Familial Hypertrophic, 20:

31
# Description HPO Frequency HPO Source Accession
1 atrial fibrillation 31 occasional (7.5%) HP:0005110
2 cardiomyopathy 31 HP:0001638
3 left ventricular hypertrophy 31 HP:0001712

Symptoms via clinical synopsis from OMIM:

56
Cardiovascular Heart:
left ventricular hypertrophy
atrial fibrillation (in some patients)
septal hypertrophy, asymmetric interventricular
left ventricular anterior wall hypertrophy (in some patients)

Clinical features from OMIM:

613876

Drugs & Therapeutics for Cardiomyopathy, Familial Hypertrophic, 20

Drugs for Cardiomyopathy, Familial Hypertrophic, 20 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
4 Neurotransmitter Agents Phase 4
5 Adrenergic Agonists Phase 4
6 Hypnotics and Sedatives Phase 4
7 Adrenergic alpha-2 Receptor Agonists Phase 4
8 Anesthetics, General Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Anesthetics, Intravenous Phase 4
11 Adrenergic Agents Phase 4
12 Neuromuscular Blocking Agents Phase 4
13 Anticonvulsants Phase 4
14 Neuromuscular Agents Phase 4
15 Neuromuscular Nondepolarizing Agents Phase 4
16 Bromides Phase 4
17
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
18
Capsaicin Approved Phase 1, Phase 2 404-86-4 1548943
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
21 Liver Extracts Phase 2
22 Micronutrients Phase 2
23 Vitamins Phase 2
24 Trace Elements Phase 2
25 Vitamin B3 Phase 2
26 Vitamin B Complex Phase 2
27 Vitamin B9 Phase 2
28 Nutrients Phase 2
29 Folate Phase 2
30 Nicotinic Acids Phase 2
31 Dermatologic Agents Phase 1, Phase 2
32 Antipruritics Phase 1, Phase 2
33
Sevoflurane Approved, Vet_approved 28523-86-6 5206
34
Ketamine Approved, Vet_approved 6740-88-1 3821
35
Lidocaine Approved, Vet_approved 137-58-6 3676
36
Sufentanil Approved, Investigational 56030-54-7 41693
37
Ethanol Approved 64-17-5 702
38
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
39
Dexamethasone acetate Approved, Investigational, Vet_approved 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved 50-02-2 5743
41
tannic acid Approved 1401-55-4
42
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
43
Magnesium Sulfate Approved, Investigational, Vet_approved 7487-88-9 24083
44
Calcium Approved, Nutraceutical 7440-70-2 271
45
Tramazoline Investigational 1082-57-1
46 Calamus
47 Antihypertensive Agents
48 Anti-Asthmatic Agents
49 Respiratory System Agents
50 Autonomic Agents

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Effects of Dexmedetomidine and Propofol on Pulmonary Mechanics Completed NCT02330120 Phase 4 propofol;dexmedetomidine
2 The Influence of a Functional Residual Capacity Guided Alveolar Recruitment Strategy After Open Endotracheal Suctioning on Oxygenation and Regional Ventilation Completed NCT00779090 Phase 4
3 Does Goal-directed Hemodynamic Therapy Driven by Endotracheal Cardiac Output Monitoring System During Surgical Intervention Reduce Hospital Stay and Major Adverse Cardiac Events Following Cardiac Surgery? Completed NCT01535716 Phase 4
4 Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS) Completed NCT01600651 Phase 4
5 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
6 Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) Unknown status NCT01225614 Phase 3
7 Noninvasive Ventilation Strategies for Early Treatment of RDS in Preterm Infants: An RCT Completed NCT02259400 Phase 2, Phase 3
8 Evaluation of CPAP (Continuous Positive Airway Pressure) in the Planning of Radiation Treatments for Lung, Upper Abdomen and Left Breast Cancers Unknown status NCT02324530 Phase 2
9 Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study. Completed NCT02017444 Phase 2 AZD4017
10 Phase 2 Study of the Alveolar Recruitment Maneuver in Cesarean Section Completed NCT01826968 Phase 2
11 Cough and Swallow Rehabilitation Following Stroke Completed NCT01907321 Phase 1, Phase 2 Measures performed on all subjects
12 Endotracheal Tube Intracuff Pressure Change After Changing Position From Neutral to Hyperextension of Neck - Comparison of a Tapered Shaped- and Cylindrical Shaped Cuff Unknown status NCT02949856
13 Prospective, Open, Uncontrolled, Non-randomized and Monocentric Trial on the Efficacy and the Inflammatory Effects of a Lung Recruitment Manoeuvre in Mechanical Ventilated Patients With Respiratory Failure Unknown status NCT01070654
14 Inspiratory Muscle Training Combined With General Exercise Training, Compared to General Exercise Training Alone in Patients With COPD: Randomized Controlled Trial Unknown status NCT02392715
15 Evaluation of Effect of Continuous Positive Air Pressure (CPAP) on Upper Airway Dimensions, by Acoustic Pharyngometry (AP), in Severe Obstructive Sleep Apnea Syndrome (OSAS) and Primary Snore Patients Unknown status NCT01210703
16 The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Intestinal Function Recovery and Infection in Neonates and Infants Undergoing Gastrointestinal Surgery: a Prospective, Randomised, Controlled Trial Unknown status NCT03056261
17 Criteria Analysis for Ventilatory Support Adjustment of Mechanical Ventilation Completed NCT02743624
18 Comparison of the Hemodynamic Safety of Two Common Alveolar Recruitment Manoeuvres With Regard to Cardiac Output in a Surgical Intensive Care Unit: a Randomized Study Completed NCT02805036
19 Airway Pressure During Nasal High Flow and CPAP in Neonates Completed NCT02632799
20 Wean Obese Study : Determination of the Optimal Spontaneous Breathing Trial for Obese Patient Completed NCT01616901
21 Effects of Sustained Inflation or Positive Pressure Ventilation on Release of Adrenomedullin in Preterm Infants With Respiratory Failure at Birth Completed NCT03437499
22 Duration of Mechanical Ventilation and Mortality Among Brain-injured Patients - a Before-after Evaluation of a Quality Improvement Project Completed NCT01885507
23 Continuous Positive Airway Pressure Decreased Lung Collapse During General Anesthesia Induction in Pediatric Patients Completed NCT03461770
24 Observational Study Evaluating the Impact of Opioid Free Anesthesia During Lung Protective Ventilation on Postoperative Oxygen Saturation. Completed NCT03660306
25 Preoperative MUCP and VLPP Failed to Predict Long Term (4-Years) Outcome in Patients Who Underwent Transobturator Mid-Urethral Slings. a Prospective Observational Descriptive Study Completed NCT00658944
26 Study of the Efficiency and Workflow of Femtosecond Laser Assisted Cataract Surgery in a Spanish Public Hospital Completed NCT03931629
27 Evaluation of Lung Volume Under Nasal High Flow With a Time of Flight Camera Completed NCT04096183
28 Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease Completed NCT02728765
29 Validation of Customer Requirements for the HC244/HC254 Completed NCT00739011
30 Low Tidal MEChanical Ventilation Against NO Ventilation During Cardiopulmonary Bypass Heart Surgery : a Randomized Controlled Trial Completed NCT03098524
31 Pulmonary Evaluation at Different Levels of PEEP: Ultrasonography Compared to Electrical Impedance Tomography (TIE) During Intraoperative Elective Surgeries Completed NCT03211936
32 Impact of Automatic Positive Airway Pressure on Treatment Compliance in Obstructive Sleep Apnea Patients Awaiting Bariatric Surgery Completed NCT02209220
33 Cerebral Oxygen Saturation, Mean Systemic Filling Pressure and Haemodynamic Effects of PEP and CPAP in Lower Body Negative Pressure Completed NCT03009305
34 Evaluation of the Additional Effect of Non Invasive Mechanical Ventilation During a Rehabilitative Program With Cycloergometer in Patients With Chronic Respiratory Insufficiency Using Nocturnal Home Ventilation Completed NCT01458314
35 Gravity- Versus Suction-driven Large Volume Thoracentesis: a Randomized Controlled Study Completed NCT03591952
36 Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease Completed NCT02176928
37 Evaluation of Different Pre-Oxygenation Conditions in Morbid Obesity: Position and Ventilation Mode, in a Respiratory Physiology Laboratory, on Voluntary Subjects Completed NCT02121808
38 A Pilot Study Comparing Infant Flow SiPAP to Noninvasive NAVA Completed NCT01588080
39 Comparison of Laryngeal Mask Airway Supreme and Endotracheal Tube In Patients Undergoing Gynecological Laparoscopy Surgery Completed NCT02127632
40 Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet Completed NCT02875379
41 Comparing the Effectiveness Between Air-Q Intubating Laryngeal Airway and Ambu® AuraGain™ Laryngeal Mask for Controlled Ventilation in Paediatric Patients: A Randomized Controlled Trial. Completed NCT03130413
42 The Performance of a Capnodynamic Method Compared to Transpulmonary Thermodilution in Open Abdominal Surgery Completed NCT03444545
43 An Investigation to Test the Efficacy of a Novel CPAP Concept to Reduce the Apnea Hypopnea Index of Patients With Obstructive Sleep Apnea Completed NCT01025440
44 Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients Completed NCT01601509 Nasal tramazoline with dexamethazone;Nasal placebo
45 Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury Completed NCT00830284
46 Protocol-directed Weaning From Mechanical Ventilation in Neurological Patients: a Controlled Trial Recruiting NCT03128086
47 Investigating the Effect of Nasal High Flow Oxygen Therapy on Regional Lung Function Recruiting NCT03821311
48 Inspiratory Muscle Training in Patients With Nemaline Myopathy Recruiting NCT03728803
49 Prospective Observational Study, Maternal Effects of Magnesium Sulphate for Neonatal Neuroprotection in Women Having Cesarean Section Under Neuraxial Anesthesia Recruiting NCT01482078
50 The Effects of Non-invasive Ventilation During Cycle Exercise Within a 3-week Pulmonary Rehabilitation Program in COPD Patients With Chronic Hypercapnic Respiratory Failure - a Randomized Controlled Trial Recruiting NCT03803358

Search NIH Clinical Center for Cardiomyopathy, Familial Hypertrophic, 20

Genetic Tests for Cardiomyopathy, Familial Hypertrophic, 20

Genetic tests related to Cardiomyopathy, Familial Hypertrophic, 20:

# Genetic test Affiliating Genes
1 Familial Hypertrophic Cardiomyopathy 20 29 NEXN
2 Cardiomyopathy, Hypertrophic, 20 29

Anatomical Context for Cardiomyopathy, Familial Hypertrophic, 20

MalaCards organs/tissues related to Cardiomyopathy, Familial Hypertrophic, 20:

40
Lung, Heart, Liver, Testes, Bone, Brain, Spinal Cord

Publications for Cardiomyopathy, Familial Hypertrophic, 20

Articles related to Cardiomyopathy, Familial Hypertrophic, 20:

(show top 50) (show all 97)
# Title Authors PMID Year
1
Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy. 56 6
20970104 2010
2
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 6
25173338 2014
3
Novel mitochondrial DNA mutations responsible for maternally inherited nonsyndromic hearing loss. 6
22241583 2012
4
HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 6
21810866 2011
5
Expression patterns of cardiac myofilament proteins: genomic and protein analysis of surgical myectomy tissue from patients with obstructive hypertrophic cardiomyopathy. 6
19808356 2009
6
Hypertrophic Cardiomyopathy Overview 6
20301725 2008
7
Mutations in sarcomere protein genes in left ventricular noncompaction. 6
18506004 2008
8
Array-based resequencing assay for mutations causing hypertrophic cardiomyopathy. 6
18258667 2008
9
Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. 6
17611253 2007
10
Gene mutations in apical hypertrophic cardiomyopathy. 6
16267253 2005
11
Molecular and muscle pathology in a series of caveolinopathy patients. 6
15580566 2005
12
Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. 6
14672715 2004
13
American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. 6
14607462 2003
14
A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. 6
12767666 2003
15
Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. 6
10966831 2000
16
An additional mitochondrial tRNA(Ile) point mutation (A-to-G at nucleotide 4295) causing hypertrophic cardiomyopathy. 6
8889580 1996
17
Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA(glycine) gene. 6
8079988 1994
18
Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. 6
7459150 1980
19
Troubleshooting Hypoxemia After Placement of an Extraglottic Airway. 61
31122593 2019
20
Respiratory variations in pulse pressure and photoplethysmographic waveform amplitude during positive expiratory pressure and continuous positive airway pressure in a model of progressive hypovolemia. 61
31560715 2019
21
Mucosal injury following short-term tracheal intubation: A novel animal model and composite tracheal injury score. 61
30186955 2018
22
Assessment of lacrimal resistance using a manometric tear duct irrigation system. 61
29405794 2018
23
Impact of positive end expiratory pressure on cerebral hemodynamic in paediatric patients with post-traumatic brain swelling treated by surgical decompression. 61
29746600 2018
24
Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. 61
28431196 2018
25
Impact of large volume paracentesis on respiratory parameters including transpulmonary pressure and on transpulmonary thermodilution derived hemodynamics: A prospective study. 61
29538440 2018
26
Low tidal volume mechanical ventilation against no ventilation during cardiopulmonary bypass heart surgery (MECANO): study protocol for a randomized controlled trial. 61
29197407 2017
27
Effectiveness of prophylactic non-invasive ventilation on respiratory function in the postoperative phase of pediatric cardiac surgery: a randomized controlled trial. 61
27706462 2016
28
Worsening Hypoxemia in the Face of Increasing PEEP: A Case of Large Pulmonary Embolism in the Setting of Intracardiac Shunt. 61
27377010 2016
29
Transcutaneous Electrical Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review. 61
26831506 2016
30
Effects of clamping procedures on central venous pressure during liver resection. 61
26633749 2016
31
Metabolomics screening identifies reduced L-carnitine to be associated with progressive emphysema. 61
26564208 2016
32
Infraclavicular axillary vein cannulation using ultrasound in a mechanically ventilated general intensive care population. 61
26310415 2015
33
[Measurement of the Minimum Pressure in the Bronchial Cuff during One-lung Ventilation Using a Capnometer]. 61
26442408 2015
34
Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. 61
26227819 2015
35
[Intrinsic sphincter deficiency and female urinary incontinence]. 61
25864653 2015
36
Impact of Extraperitoneal Dioxyde Carbon Insufflation on Respiratory Function in Anesthetized Adults: A Preliminary Study Using Electrical Impedance Tomography and Wash-out/Wash-in Technic. 61
25789238 2015
37
Effect of positive end-expiratory pressure on porcine right ventricle function assessed by speckle tracking echocardiography. 61
25873786 2015
38
Increased intracranial pressure in spontaneous CSF leak patients is not associated with papilledema. 61
25248848 2014
39
A Valsalva leak-point pressure of >100 cmH2O is associated with greater success in AdVance™ sling placement for the treatment of post-prostatectomy urinary incontinence. 61
24796275 2014
40
Heart-lung interactions during neurally adjusted ventilatory assist. 61
25212533 2014
41
Assessment of right liver graft perfusion effectiveness between one and two-catheter infusion methods. 61
26155247 2014
42
Tidal stretches differently regulate the contractile and cytoskeletal elements in intact airways. 61
24740101 2014
43
Current ventilation practice during general anaesthesia: a prospective audit in Melbourne, Australia. 61
25302048 2014
44
Comparison of three high flow oxygen therapy delivery devices: a clinical physiological cross-over study. 61
23857440 2013
45
Repeat mid-urethral sling for recurrent female stress urinary incontinence. 61
22976532 2013
46
Detrusor underactivity is prevalent after radical prostatectomy: A urodynamic study including risk factors. 61
22277630 2013
47
Predictive value of obstructive voiding symptoms and objective bladder emptying tests for urinary retention. 61
23075353 2012
48
Inspiratory muscle training in patients with heart failure: meta-analysis of randomized trials. 61
22964897 2012
49
[Difficult ventilation after sugammadex administration: a case report]. 61
22860306 2012
50
Comparison of superior vena cava and femoroiliac vein pressure according to intra-abdominal pressure. 61
22742667 2012

Variations for Cardiomyopathy, Familial Hypertrophic, 20

ClinVar genetic disease variations for Cardiomyopathy, Familial Hypertrophic, 20:

6 (show top 50) (show all 64) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NEXN NM_144573.3(NEXN):c.391C>G (p.Gln131Glu)SNV Pathogenic 30993 rs387907079 1:78383902-78383902 1:77918217-77918217
2 NEXN NM_144573.3(NEXN):c.835C>T (p.Arg279Cys)SNV Conflicting interpretations of pathogenicity 30994 rs146245480 1:78392548-78392548 1:77926863-77926863
3 NEXN NM_001172309.1(NEXN):c.1479_1481GGA[3] (p.Glu498del)short repeat Conflicting interpretations of pathogenicity 201945 rs397517848 1:78408155-78408157 1:77942470-77942472
4 NEXN NM_001172309.1(NEXN):c.1754_1756GAG[1] (p.Gly586del)short repeat Conflicting interpretations of pathogenicity 47899 rs397517853 1:78408435-78408437 1:77942746-77942748
5 NEXN NM_144573.3(NEXN):c.1918_1922del (p.Tyr640fs)deletion Conflicting interpretations of pathogenicity 470680 rs1222794437 1:78408401-78408405 1:77942716-77942720
6 NEXN NM_144573.3(NEXN):c.1955A>G (p.Tyr652Cys)SNV Conflicting interpretations of pathogenicity 326 rs137853197 1:78408441-78408441 1:77942756-77942756
7 NEXN NM_144573.3(NEXN):c.277G>C (p.Ala93Pro)SNV Uncertain significance 470682 rs1256690084 1:78383702-78383702 1:77918017-77918017
8 NEXN NM_144573.3(NEXN):c.1994G>T (p.Ser665Ile)SNV Uncertain significance 538111 rs777703689 1:78408480-78408480 1:77942795-77942795
9 NEXN NM_144573.3(NEXN):c.491A>G (p.Glu164Gly)SNV Uncertain significance 538106 rs1553238441 1:78392100-78392100 1:77926415-77926415
10 NEXN NM_144573.3(NEXN):c.767G>A (p.Arg256Gln)SNV Uncertain significance 538105 rs748921688 1:78392480-78392480 1:77926795-77926795
11 NEXN NM_144573.3(NEXN):c.1348dup (p.Ser450fs)duplication Uncertain significance 538107 rs1553240600 1:78401599-78401600 1:77935914-77935915
12 NEXN NM_001172309.1(NEXN):c.1709_1712delinsTCT (p.Gly570fs)indel Uncertain significance 538109 rs1553242300 1:78408387-78408390 1:77942702-77942705
13 NEXN NM_144573.3(NEXN):c.818G>A (p.Arg273His)SNV Uncertain significance 538110 rs765385072 1:78392531-78392531 1:77926846-77926846
14 NEXN NM_144573.3(NEXN):c.1244T>C (p.Met415Thr)SNV Uncertain significance 538108 rs1172366391 1:78399157-78399157 1:77933472-77933472
15 NEXN NM_144573.3(NEXN):c.643C>G (p.Gln215Glu)SNV Uncertain significance 569703 rs1557981819 1:78392252-78392252 1:77926567-77926567
16 NEXN NM_144573.3(NEXN):c.752T>G (p.Phe251Cys)SNV Uncertain significance 575147 rs554389574 1:78392465-78392465 1:77926780-77926780
17 NEXN NM_144573.3(NEXN):c.250G>A (p.Glu84Lys)SNV Uncertain significance 582416 rs547319928 1:78383675-78383675 1:77917990-77917990
18 NEXN NM_144573.3(NEXN):c.1664_1666del (p.Arg555_Glu556delinsLys)deletion Uncertain significance 575564 rs1221963637 1:78408150-78408152 1:77942465-77942467
19 NEXN NM_144573.3(NEXN):c.134G>T (p.Arg45Ile)SNV Uncertain significance 643060 1:78383357-78383357 1:77917672-77917672
20 NEXN NM_144573.3(NEXN):c.431C>T (p.Ala144Val)SNV Uncertain significance 662564 1:78383942-78383942 1:77918257-77918257
21 NEXN NM_144573.3(NEXN):c.542C>T (p.Thr181Ile)SNV Uncertain significance 661519 1:78392151-78392151 1:77926466-77926466
22 NEXN NM_144573.3(NEXN):c.857G>A (p.Arg286Gln)SNV Uncertain significance 645036 1:78392570-78392570 1:77926885-77926885
23 NEXN NM_144573.3(NEXN):c.1046G>C (p.Arg349Thr)SNV Uncertain significance 649140 1:78395182-78395182 1:77929497-77929497
24 NEXN NM_144573.3(NEXN):c.1055T>C (p.Val352Ala)SNV Uncertain significance 662435 1:78398968-78398968 1:77933283-77933283
25 NEXN NM_144573.3(NEXN):c.1697T>C (p.Met566Thr)SNV Uncertain significance 641866 1:78408183-78408183 1:77942498-77942498
26 NEXN NM_144573.3(NEXN):c.1739G>A (p.Gly580Glu)SNV Uncertain significance 664341 1:78408225-78408225 1:77942540-77942540
27 NEXN NM_144573.3(NEXN):c.1877A>G (p.Glu626Gly)SNV Uncertain significance 665536 1:78408363-78408363 1:77942678-77942678
28 NEXN NM_144573.3(NEXN):c.2008A>T (p.Thr670Ser)SNV Uncertain significance 658474 1:78408494-78408494 1:77942809-77942809
29 NEXN NM_144573.3(NEXN):c.613G>A (p.Glu205Lys)SNV Uncertain significance 47908 rs201447781 1:78392222-78392222 1:77926537-77926537
30 NEXN NM_144573.3(NEXN):c.687+4A>TSNV Uncertain significance 241866 rs754061340 1:78392300-78392300 1:77926615-77926615
31 NEXN NM_144573.3(NEXN):c.392A>C (p.Gln131Pro)SNV Uncertain significance 264597 rs397517858 1:78383903-78383903 1:77918218-77918218
32 NEXN NM_144573.3(NEXN):c.86G>T (p.Gly29Val)SNV Uncertain significance 229061 rs876657931 1:78383309-78383309 1:77917624-77917624
33 NEXN NM_144573.3(NEXN):c.379C>T (p.Arg127Cys)SNV Uncertain significance 229058 rs771113424 1:78383890-78383890 1:77918205-77918205
34 NEXN NM_144573.3(NEXN):c.1174C>T (p.Arg392Ter)SNV Uncertain significance 229051 rs750076188 1:78399087-78399087 1:77933402-77933402
35 NEXN NM_144573.3(NEXN):c.1415C>G (p.Ala472Gly)SNV Uncertain significance 229054 rs539665448 1:78401671-78401671 1:77935986-77935986
36 NEXN NM_144573.3(NEXN):c.671G>A (p.Cys224Tyr)SNV Uncertain significance 298088 rs886046534 1:78392280-78392280 1:77926595-77926595
37 NEXN NM_144573.3(NEXN):c.902T>A (p.Ile301Asn)SNV Uncertain significance 409281 rs373878384 1:78395038-78395038 1:77929353-77929353
38 NEXN NM_144573.3(NEXN):c.1852G>A (p.Glu618Lys)SNV Uncertain significance 409282 rs1060502321 1:78408338-78408338 1:77942653-77942653
39 NEXN NM_144573.3(NEXN):c.1687G>T (p.Gly563Cys)SNV Uncertain significance 417868 rs1060499571 1:78408173-78408173 1:77942488-77942488
40 NEXN NM_144573.3(NEXN):c.871G>A (p.Glu291Lys)SNV Uncertain significance 470684 rs770120245 1:78395007-78395007 1:77929322-77929322
41 NEXN NM_144573.3(NEXN):c.586C>T (p.Arg196Cys)SNV Uncertain significance 179003 rs369486891 1:78392195-78392195 1:77926510-77926510
42 NEXN NM_144573.3(NEXN):c.1429A>G (p.Ile477Val)SNV Uncertain significance 470678 rs1553240667 1:78401685-78401685 1:77936000-77936000
43 NEXN NM_144573.3(NEXN):c.1997C>A (p.Thr666Asn)SNV Uncertain significance 470681 rs749271412 1:78408483-78408483 1:77942798-77942798
44 NEXN NM_144573.3(NEXN):c.1053+1G>ASNV Uncertain significance 47886 rs397517843 1:78395190-78395190 1:77929505-77929505
45 NEXN NM_144573.3(NEXN):c.1112C>T (p.Pro371Leu)SNV Uncertain significance 47887 rs200067011 1:78399025-78399025 1:77933340-77933340
46 NEXN NM_001172309.1(NEXN):c.1209_1211AGA[2] (p.Glu406del)short repeat Uncertain significance 47890 rs397517846 1:78401657-78401659 1:77935972-77935974
47 NEXN NM_144573.3(NEXN):c.1457C>G (p.Ala486Gly)SNV Uncertain significance 47892 rs397517847 1:78401713-78401713 1:77936028-77936028
48 NEXN NM_001172309.1(NEXN):c.1561_1563AAG[1] (p.Lys522del)short repeat Uncertain significance 47896 rs397517851 1:78408239-78408241 1:77942554-77942556
49 NEXN NM_144573.3(NEXN):c.1788T>G (p.Ser596Arg)SNV Uncertain significance 47897 rs199738750 1:78408274-78408274 1:77942589-77942589
50 NEXN NM_144573.3(NEXN):c.1572_1574delAGAshort repeat Uncertain significance 194130 rs764505909 1:78407806-78407808 1:77942121-77942123

UniProtKB/Swiss-Prot genetic disease variations for Cardiomyopathy, Familial Hypertrophic, 20:

73
# Symbol AA change Variation ID SNP ID
1 NEXN p.Gln131Glu VAR_065477 rs387907079
2 NEXN p.Arg279Cys VAR_065478 rs146245480

Expression for Cardiomyopathy, Familial Hypertrophic, 20

Search GEO for disease gene expression data for Cardiomyopathy, Familial Hypertrophic, 20.

Pathways for Cardiomyopathy, Familial Hypertrophic, 20

Pathways related to Cardiomyopathy, Familial Hypertrophic, 20 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.55 IL6 IL13 CXCL8
2 11.35 IL6 IL13 CXCL8
3 11.02 IL6 IL13 CXCL8
4 10.72 IL6 IL13 ELN CXCL8
5 10.59 IL6 IL13 CD4

GO Terms for Cardiomyopathy, Familial Hypertrophic, 20

Biological processes related to Cardiomyopathy, Familial Hypertrophic, 20 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 8.92 IL6 IL13 CXCL8 CD4

Sources for Cardiomyopathy, Familial Hypertrophic, 20

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....